CrossRef Characteristics of serum bile acid profiles among individuals with metabolic dysfunction-associated steatotic liver disease Sheng Lyu, Jiani Yang, Xin Xin, Qinmei Sun, Beiyu Cai, Xin Wang, Ziming An, Jian Sun, Yiyang Hu, Lei Shi, Qin Feng, Xiaojun Gou BMC Gastroenterology .2025;[Epub] CrossRef Harnessing nutrition to combat MASLD: a comprehensive guide to food-based therapeutic strategies Claudia Reytor-Gonzlez, Daniel Simancas-Racines, Martn Campuzano-Donoso, Janeth Castano Jimenez, Nthaly Mercedes Romn-Galeano, Gerardo Sarno, Evelyn Frias-Toral Food and Agricultural Immunology .2025;[Epub] CrossRef Association between urinary albumin-to-creatinine ratio and all-cause and cardiovascular-cause mortality among MASLD: NHANES 20012018 Zhengjin Wang, Zhangxin Chen, Hanxu Zhuang Frontiers in Nutrition .2025;[Epub] CrossRef Anthropometric Measures and Mortality Risk in Individuals With Metabolic DysfunctionAssociated Steatotic Liver Disease (MASLD): A PopulationBased Cohort Study Yee Hui Yeo, Yixuan Zhu, Jingli Gao, Shanghao Liu, Wenjing Ni, Fajuan Rui, Xue Bai, Nan Geng, Rui Jin, Elizabeth K
Consistency matters : Results take weeks to months, depending on skin tone
The confidence in estimates for comparisons between tirzepatide and semaglutide was high to moderate, except for comparisons vs semaglutide 2.0 mg, where the confidence was low (ESM Table 12)
Researchers studying metabolic dysfunction in adipose tissue have identified NNMT as one of the most consistently upregulated enzymes in obese white fat, making it a high-confidence therapeutic target for metabolic intervention
GLP-1-directed NMDA receptor antagonism for obesity treatment
